A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

NCT02857270 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer
Metastatic Melanoma
Metastatic Non-small Cell Lung Cancer
Colorectal Cancer

Interventions

DRUG: LY3214996
DRUG: Midazolam
DRUG: Abemaciclib
DRUG: Nab-paclitaxel
DRUG: Gemcitabine
DRUG: Encorafenib
DRUG: Cetuximab

Sponsor

Eli Lilly and Company